← Human Trials & Peer-Reviewed Studies
Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes.
Plain-language guide to PMID 7684551 (1993): double-blind controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 subjects.
Key Facts
- PMID
- 7684551
- Journal
- Acta endocrinologica
- Year
- 1993
- Study type
- Controlled Clinical Trial
- Authors
- Deyssig R et al. (4 authors)
- DOI
- 10.1530/acta.0.1280313
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.
The effect of recombinant GH on strength, body composition and endocrine parameters in power athletes was investigated in a controlled study.
To exclude concurrent treatment with androgenic-anabolic steroids urine specimens were tested at regular intervals for these substances.
Who Took Part
According to the abstract, 8 subjects were involved.
The age groups tagged for this paper are adults, men only.
How the Study Was Run
The design is described as double-blind and placebo-controlled.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Maximal voluntary strength of the biceps and quadriceps muscles was measured on a strength training apparatus.
What Was Measured
To exclude concurrent treatment with androgenic-anabolic steroids urine specimens were tested at regular intervals for these substances.
Fat mass and lean body mass were derived from measurements of skinfolds at ten sites with a caliper.
Topics PubMed links to this paper include Body Composition, Body Mass Index, Carrier Proteins, Growth Hormone, Growth Inhibitors, Hormones and Insulin-Like Growth Factor Binding Proteins.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1993 (Acta endocrinologica), a journal based in Denmark.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.